You are here

Generic Version of Phenergan Approved

SOUTH PLAINFIELD, N.J., July 1 /PRNewswire-FirstCall/ -- ABLE LABORATORIES, INC. , today announced that it has received Food and Drug Administration approval for its Abbreviated New Drug Applications for Promethazine Hydrochloride Tablets, USP 12,5mg, 25mg and 50mg, which are therapeutically equivalent to Phenergan® Tablets 12.5mg, 25mg and 50mg of Wyeth Ayerst Laboratories. The total sales for Able's newly approved drugs (used in the treatment of nausea and vomiting associated with certain types of anesthesia and surgery), is estimated to be approximately $70 million according to recent market data.

Able is the first company to offer AB-Rated generic version of Promethazine Hydrochloride Tablets, USP 12.5mg and the only company to market AB-Rated generic version of all three tablet products. This approval, along with Able's Promethazine Hydrochloride suppository products, represents the expansion of Able's line of Promethazine-based products.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Further information on Able may be found on the Company's web site,

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key